


In the Claims:

A complete listing of claims 1-48 with status identifier follows.

Claim 1 (Currently Amended): A compound of formula (I)



or a salt or solvate thereof, ~~or physiologically functional derivative thereof;~~

wherein

X is CR¹ and Y is N;
~~or X is N and Y is CR¹;~~
~~or X is CR¹ and Y is CR²;~~
or X is CR² and Y is CR¹;

R¹ represents a group R⁵SO₂CH₂CH₂Z-(CH₂)_p-Ar-, wherein Ar is ~~selected from phenyl,~~
furan, thiophene, pyrrole and thiazole, ~~each of which may optionally be substituted by~~
one or two halo, C₁₋₄ alkyl or C₁₋₄ alkoxy groups; Z represents O, S, NH or NR⁶; p is 1, 2,
3 or 4;

R⁵ is C₁₋₆ alkyl optionally substituted by one or more R⁶ groups; or

R⁵ is C₁₋₆ alkyl substituted by a 5 to 10-membered heterocyclic group or a 3 to 10-
membered carbocyclic group, each of which may be optionally substituted by one or
more R⁶ groups; or

R⁵ is selected from the group consisting of a 5 to 10-membered heterocyclic group or a 3
to 10-membered carbocyclic group, each of which may be optionally substituted by one
or more R⁶ groups;

each R^8 is independently selected from halo, hydroxy, C_{1-4} alkoxy, nitrile, NH_2 or NR^6R^7 ;

R^8 is C_{1-4} alkyl, C_{1-4} alkoxy- C_{1-4} alkyl, hydroxy C_{1-4} alkyl, $CF_3C(O)$ or $CH_3C(O)$;

R^7 is hydrogen or R^6 ;

R^2 is selected from hydrogen, halo, hydroxy, C_{1-4} alkyl and C_{1-4} alkoxy;

R^3 is selected from pyridylmethoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy;

R^4 is selected from hydrogen, halogen, C_{1-4} alkyl, C_{2-4} alkynyl or cyano [[:]]

with the proviso that when p is 1 and Z is NH , R^6 cannot represent CH_3 .

Claim 2 (Original): The compound of claim 1, wherein X is CR^1 and Y is CR^2 .

Claim 3 (Cancelled):

Claim 4 (Original): The compound of claim 1, wherein R^2 is hydrogen, halogen or C_{1-4} alkoxy.

Claim 5 (Original): The compound of claim 1, wherein R^2 is hydrogen, fluoro or methoxy.

Claim 6 (Original): The compound of claim 1, wherein R^2 is hydrogen or fluoro.

Claim 7 (Original): The compound of claim 1, wherein Z is NH , NR^6 or O .

Claim 8 (Original): The compound of claim 1, wherein Z is NH or O .

Claim 9 (Original): The compound of claim 1, wherein Z is NH .

Claim 10 (Original): The compound of claim 1, wherein p is 1, 2 or 3.

Claim 11 (Original): The compound of claim 1, wherein Ar does not carry any optional substituents.

Claim 12 (Currently Amended): The compound of claim 1, wherein Ar is furan or thiazole.

Claim 13 (Original): The compound of claim 1, wherein R⁵ is an aromatic heterocyclic or carbocyclic group optionally substituted by a C₁₋₄ alkyl group.

Claim 14 (Original): The compound of claim 1, wherein R⁵ is pyridyl, phenyl, imidazolyl or N-methylimidazolyl.

Claim 15 (Currently Amended): The compound of claim 1, wherein R⁵ is C₁₋₆ alkyl optionally substituted by one or more groups selected from halo, hydroxy, C₁₋₄ alkoxy, nitrile, NH₂ or NR⁶R⁷.

Claim 16 (Currently Amended): The compound of claim 1, wherein R⁵ is C₁₋₆ alkyl optionally substituted by one or more groups selected from hydroxy, C₁₋₄ alkoxy, NH₂ or NR⁶R⁷, wherein R⁶ represents C₁₋₄ alkyl.

Claim 17 (Cancelled):

Claim 18 (Original): The compound of claim 1, wherein R³ is benzyloxy or fluorobenzyloxy.

Claim 19 (Original): The compound of claim 1, wherein R⁴ is chloro, bromo, or hydrogen.

Claim 20 (Original): The compound of claim 1, wherein R³ is benzyloxy or 3-fluorobenzyloxy and R⁴ is chloro or bromo.

Claim 21 (Currently Amended): The compound of claim 1, wherein Y is CR², R² is hydrogen, fluoro or methoxy; X is CR¹, Ar is unsubstituted furan or thiazole; R³ is benzyloxy or fluorobenzyloxy; and R⁴ is hydrogen, chloro or bromo.

Claim 22 (Currently Amended): The compound of claim 1, where in X is CR², R² is hydrogen, fluoro or methoxy; Y is CR¹, Ar is unsubstituted furan or ~~thiazole~~; R³ is benzyloxy or fluorobenzyloxy; and R⁴ is hydrogen, chloro or bromo.

Claim 23 (Cancelled):

Claim 24 (Currently Amended): The compound of claim 1, wherein Y is CR², R² is hydrogen, fluoro or methoxy; X is CR¹, Ar is unsubstituted furan or ~~thiazole~~; R³ is fluorobenzyloxy; and R⁴ is chloro or bromo.

Claims 25-30 (Cancelled):

Claim 31 (Currently Amended): The compound of claim 1, wherein Y is CR², R² is hydrogen, fluoro or methoxy; X is CR¹, Ar is unsubstituted furan or ~~thiazole~~; R³ is benzyloxy or fluorobenzyloxy; R⁴ is hydrogen, chloro or bromo; and R⁵ is pyridine, imidazole, or phenyl.


Claim 32 (Currently Amended): The compound of claim 1, wherein X is CR², R² is hydrogen, fluoro or methoxy; Y is CR¹, Ar is unsubstituted furan or ~~thiazole~~; R³ is benzyloxy or fluorobenzyloxy; R⁴ is hydrogen, chloro or bromo; and R⁵ is pyridine, imidazole, or phenyl.

Claim 33 (Cancelled):

Claim 34 (Currently Amended): The compound of claim 1, wherein Y is CR², R² is hydrogen, fluoro or methoxy; X is CR¹, Ar is unsubstituted furan or ~~thiazole~~; R³ is fluorobenzyloxy; R⁴ is chloro or bromo; and R⁵ is pyridine, imidazole, or phenyl.

Claim 35 (Cancelled):

Claim 36 (Previously Presented): A compound wherein the compound is a compound of formula (I')



Claim 37 (Currently Amended): A compound of claim 1 selected from

(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-phenylsulphonyl-ethylamino)-propyl)-furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-(2-N-methylimidazolyl)-sulphonyl-ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;
~~(4-(3-Fluorobenzoyloxy)-phenyl)-(6-(2-((2-propanesulphonyl-ethylamino)-methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;~~
~~(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-propanesulphonyl-ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~
~~(4-Benzoyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-propyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~
~~(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-iso-propyl-sulphonyl-ethylamino)-propyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~
~~(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-propanesulphonyl-ethylamino)-propyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~
~~(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine;~~
~~4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-ethyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~

and salts [[,]] or solvates ~~or physiologically functional derivatives thereof.~~

Claim 38 (Currently Amended): A compound of claim 1 selected from

N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-(5-[(2-(phenylsulfonyl)ethoxy)methyl]-2-furyl)-4-quinazolinamine;
(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-phenylsulphonyl-ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzoyloxy)-3-chlorophenyl)-(6-(2-((2-(2-pyridyl)-sulphonyl-ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;
N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-(5-[(2-(methylsulfonyl)ethoxy)methyl]-2-furyl)-4-quinazolinamine;
N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-(5-[(2-(vinylsulfonyl)ethoxy)methyl]-2-furyl)-4-quinazolinamine;
~~2-[[[5-(4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)-6-quinazolinyl)-2-furyl)methyl][2-(methylsulfonyl)ethyl]amino]acetonitrile;~~
~~6-[5-[(benzyl[2-(methylsulfonyl)ethyl]amino)methyl]-2-furyl]-N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-4-quinazolinamine;~~

~~N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-[5-((ethyl(2-methylsulfonyl)ethyl)amino)methyl)-2-furyl]-4-quinazolinamine;~~
~~N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-[5-(((2-methylsulfonyl)ethyl)(propyl)amino)methyl)-2-furyl]-4-quinazolinamine;~~
~~(4-(3-Fluorobenzyl)oxy)-3-chlorophenyl)-(6-(2-((2-iso-propyl-sulphenyl-ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;~~

and salts [[.]] or solvates, ~~or physiologically functional derivatives thereof.~~

Claim 39 (Previously Presented): A pharmaceutical composition, comprising: a therapeutically effective amount of at least one compound as claimed in claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients.

Claim 40 (Previously Presented): A method of treating a human or animal subject suffering from a disorder mediated by aberrant protein kinase activity, comprising administering to said mammal a therapeutically effective amount of at least one compound as claimed in claim 1.

Claim 41 (Original): The method of claim 40, wherein the disorder is cancer or psoriasis.

Claim 42 (Original) The method of claim 40, wherein two or more protein kinases selected from c-ERB-B2, c-ERB-B4, or EGFr, exhibit aberrant activity.

Claim 43 (Original): The method of claim 40, wherein c-ERB-B2 and EGFr exhibit aberrant activity,

Claims 44-48 (Cancelled):